Searches , social queries for CERITINIB
Search references for CERITINIB. Phrases containing CERITINIB
See searches and references containing CERITINIB!
Search references for CERITINIB. Phrases containing CERITINIB
See searches and references containing CERITINIB!CERITINIB
ALK inhibitor for treatment of non-small-cell lung cancer
Ceritinib (INN, trade name Zykadia /zaɪˈkeɪdiːə/ zy-KAY-dee-ə) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC)
Ceritinib
Class of pharmaceutical drugs
and targeting a broader set of resistance mutations. As such, Novartis' ceritinib was approved by the FDA in April 2014 for treatment of NSCLC. It provided
ALK_inhibitor
Malignant tumor characterized by uncontrolled cell growth in lung tissue
ALK inhibitors crizotinib, or its successors alectinib, brigatinib, and ceritinib. Those treated with ALK inhibitors who relapse can then be treated with
Lung_cancer
Medication
Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK Alectinib Brigatinib Ceritinib Crizotinib Ensartinib Lorlatinib RET inhibitors: Entrectinib (ALK, ROS1
Zilurgisertib
Topics referred to by the same term
in Rwanda Living room, Dining room, Kitchen, in Japanese accommodation Ceritinib or LDK378, a cancer drug This disambiguation page lists articles associated
LDK
Medication
Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK Alectinib Brigatinib Ceritinib Crizotinib Ensartinib Lorlatinib RET inhibitors: Entrectinib (ALK, ROS1
Elranatamab
Protein found in humans
days of treatment. Treatment must be continued indefinitely at present. Ceritinib was approved by the FDA in April 2014 for the treatment of patients with
Anaplastic_lymphoma_kinase
Medical condition
brand name Xalkori and Crizalk that targets the EML4/ALK fusion gene. Ceritinib is a second generation targeted therapy (FDA approved in 2014), manufactured
ALK_positive_lung_cancer
Protein-coding gene in the species Homo sapiens
certain resistance mutations that develop during treatment with crizotinib. Ceritinib demonstrates clinical activity (including treating the brain) in ROS1+
ROS1
Enzyme that metabolizes substances by oxidation
as those increasing the AUC of digoxin to ≥1.25-fold); telithromycin ceritinib mibefradil (used for the treatment of hypertension and chronic angina
CYP3A4
Class of drugs used to treat malignant tumors
Inhibits MEK1 and MEK2 serine/threonine kinases Occasional adverse reactions Ceritinib ALK-positive metastatic non-small-cell lung cancer Inhibits ALK and other
Antineoplastic
Kinase inhibitor for treatment of non-small-cell lung cancer
for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first anaplastic lymphoma kinase inhibitor therapy for metastatic
Lorlatinib
Monoclonal antibody
Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK Alectinib Brigatinib Ceritinib Crizotinib Ensartinib Lorlatinib RET inhibitors: Entrectinib (ALK, ROS1
Mosunetuzumab
Pharmaceutical drug classification
Dabrafenib L01EC03 Encorafenib L01EC04 Tovorafenib L01ED01 Crizotinib L01ED02 Ceritinib L01ED03 Alectinib L01ED04 Brigatinib L01ED05 Lorlatinib L01EE01 Trametinib
ATC_code_L01
Lung cancer of glandular origin or characteristics
crizotinib benefited from second-generation ALK inhibitors including ceritinib, alectinib and brigatinib. Resistance to ALK inhibitors can occur with
Adenocarcinoma_of_the_lung
Pembrolizumab Merck Sharp & Dohme microsatellite instability-high tumors Ceritinib Novartis Pharmaceuticals ALK-positive, metastatic non-small cell lung
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Enzyme protein
metronidazole (antibiotic and antiprotozoal medication) phenylbutazone Weak ceritinib quercetin (a plant-based flavonol) Unspecified potency antihistamines
CYP2C9
Medicinal chemist
the development of multiple new drug launches, for example nilotinib, ceritinib, panobinostat, and Entresto. Briner left Novartis in late 2022, and is
Karin_Briner
CH5424802 (Chugai Pharmaceutical Co.) ASP3026 (Astellas Pharma Inc.) Ceritinib (LDK378, Novartis Pharmaceuticals) AP26113 (Ariad Pharmaceuticals) Crizotinib
Targeted molecular therapy for neuroblastoma
Targeted_molecular_therapy_for_neuroblastoma
Medical condition
retreatment with crizotinib (1 case) or a second generation ALK inhibitor, ceritinib (1 case). A study of 14 pediatric patients with metastatic or inoperable
Inflammatory myofibroblastic tumour
Inflammatory_myofibroblastic_tumour
travel, tourism, insurance
CERITINIB
CERITINIB
CERITINIB
CERITINIB
CERITINIB
CERITINIB
CERITINIB
CERITINIB
CERITINIB
travel, tourism, insurance